Search

Displaying results 541 - 550 of 4300 in total
  1. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.

  2. Drug

    Griseofulvin

    go.drugbank.com/drugs/DB00400
    ApprovedVet approved

    Griseofulvin may be given by mouth in the treatment of tinea infections.

  3. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    of illnesses caused by other protozoa or helminths [A31976]. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

  7. Drug

    Montelukast

    go.drugbank.com/drugs/DB00471
    ApprovedInvestigational

    official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L6328,L6331] the drug still sees extensive use worldwide via millions of prescriptions annually and has since become available … Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.

  8. Drug

    Inositol

    go.drugbank.com/drugs/DB13178
    ApprovedInvestigationalWithdrawn

    [L2560] Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued. … Inositol is a collection of nine different stereoisomers but the name is usually used to describe only the most common type of inositol, myo-inositol.

  9. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901] … Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor

  10. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S.